期刊
INTERNATIONAL IMMUNOLOGY
卷 27, 期 1, 页码 55-62出版社
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxu102
关键词
anti-cytokine therapy; atherosclerosis; fibrosis; fractures; rheumatoid arthritis
类别
资金
- Arthritis Research Campaign, Centocor Inc.
- Medical Research Council
- Wellcome Trust
- Nuffield Foundation
While for a century therapeutics has been dominated by small molecules, i.e. organic chemicals of similar to 400 Da absorbable via the gut, this is no longer the case. There are now a plethora of important medicines which are proteins and injectable, which have dramatically improved the therapy of many inflammatory diseases and of cancer. Most of these are monoclonal antibodies, some are receptor ig Fc fusion proteins, others are cytokines or enzymes. The key to this new aspect of therapeutics has been the filling of unmet needs, and the consequent commercial success, which promoted further research and development. The first 'biologic' for a common disease, rheumatoid arthritis (RA), was a monoclonal antibody, infliximab, to human tumour necrosis factor (TNF). This was based on our work, which is described in this review, summarizing how TNF was defined as a good target in RA, how it was developed is described here, as well as future indications for anti-TNF and related agents. Biologics are now the fastest growing sector of therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据